» Articles » PMID: 25293880

Mitochondrial DNA Copy Number and Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma Risk in Two Prospective Studies

Abstract

Background: Mitochondrial DNA copy number (mtDNA CN) may be modified by mitochondria in response to oxidative stress. Previously, mtDNA CN was associated with non-Hodgkin lymphoma (NHL) risk, particularly chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We conducted a replication study in the Prostate, Lung, Colorectal, and Ovarian (PLCO) study and pooled with published ATBC (Alpha-Tocopherol, Beta-Carotene) data.

Methods: In PLCO, 292 NHL cases (95 CLL/SLL cases) and 301 controls were pooled with 142 NHL cases (47 CLL/SLL cases) and 142 controls from ATBC. Subjects answered a questionnaire and provided blood. DNA was extracted from prediagnostic peripheral white blood, and mtDNA CN assayed by quantitative polymerase chain reaction. Unconditional logistic regression estimated mtDNA CN and NHL risk by odds ratios (OR) and 95% confidence intervals (95% CI).

Results: Greater mtDNA CN was associated with increased risk of CLL/SLL among males in PLCO (3rd vs. 1st tertile: OR, 2.21; 95% CI, 1.03-4.72; Ptrend: 0.049) and pooled (T3 vs. T1: OR, 3.12; 95% CI, 1.72-5.68; Ptrend: 0.0002). Association was stronger among male smokers (Ptrend: <0.0001) and essentially identical for cases diagnosed <6, >6-8, and >8 years from blood draw (pooled: Pinteraction: 0.65). mtDNA CN and risk of other NHL subtypes and multiple myeloma showed no association.

Conclusions And Impact: Mitochondrial DNA CN was associated with risk of CLL/SLL in males/male smokers. The risk was observed among cases diagnosed as long as 8 years after blood draw. These results suggest that higher mtDNA CN may reflect a process involved in CLL/SLL development.

Citing Articles

Genetic association between mitochondrial DNA copy number and glioma risk: insights from causality.

He Q, Wang W, Xu D, Xiong Y, Tao C, Ma L BMC Cancer. 2024; 24(1):1439.

PMID: 39574033 PMC: 11583505. DOI: 10.1186/s12885-024-13212-7.


Effect of Diet and Oxidative Stress in the Pathogenesis of Lymphoproliferative Disorders.

Cancemi G, Cicero N, Allegra A, Gangemi S Antioxidants (Basel). 2023; 12(9).

PMID: 37759977 PMC: 10525385. DOI: 10.3390/antiox12091674.


Targeting Redox Regulation as a Therapeutic Opportunity against Acute Leukemia: Pro-Oxidant Strategy or Antioxidant Approach?.

Allegra A, Tonacci A, Giordano L, Musolino C, Gangemi S Antioxidants (Basel). 2022; 11(9).

PMID: 36139768 PMC: 9495346. DOI: 10.3390/antiox11091696.


Peripheral blood leukocyte mitochondrial DNA content and risk of lung cancer.

Kennedy G, Mitra N, Penning T, Whitehead A, Vachani A Transl Lung Cancer Res. 2022; 11(7):1268-1278.

PMID: 35958326 PMC: 9359958. DOI: 10.21037/tlcr-21-979.


GWAS and ExWAS of blood mitochondrial DNA copy number identifies 71 loci and highlights a potential causal role in dementia.

Chong M, Mohammadi-Shemirani P, Perrot N, Nelson W, Morton R, Narula S Elife. 2022; 11.

PMID: 35023831 PMC: 8865845. DOI: 10.7554/eLife.70382.


References
1.
Liao L, Baccarelli A, Shu X, Gao Y, Ji B, Yang G . Mitochondrial DNA copy number and risk of gastric cancer: a report from the Shanghai Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2011; 20(9):1944-9. PMC: 3169741. DOI: 10.1158/1055-9965.EPI-11-0379. View

2.
Hosgood 3rd H, Liu C, Rothman N, Weinstein S, Bonner M, Shen M . Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis. 2010; 31(5):847-9. PMC: 2864414. DOI: 10.1093/carcin/bgq045. View

3.
Bonner M, Shen M, Liu C, DiVita M, He X, Lan Q . Mitochondrial DNA content and lung cancer risk in Xuan Wei, China. Lung Cancer. 2008; 63(3):331-4. PMC: 2966769. DOI: 10.1016/j.lungcan.2008.06.012. View

4.
Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei X . Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life. 2007; 59(7):450-7. DOI: 10.1080/15216540701509955. View

5.
Hayes R, Sigurdson A, Moore L, Peters U, Huang W, Pinsky P . Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005; 592(1-2):147-54. DOI: 10.1016/j.mrfmmm.2005.06.013. View